ReviewProstate cancer and prostatic diseases2022
Disparities in germline testing among racial minorities with prostate cancer.
Review in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).Prostate cancer and prostatic diseases · 2025Guideline
- Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO precision oncology · 2022Trial
- Real-World Actionability Analysis of Comprehensive Genomic Profiling Versus Single/Small-Gene Panels.Oncology and therapy · 2026Article
- Factors contributing to the underdiagnosis of hereditary transthyretin amyloidosis (hATTR) in Black patients.Journal of community genetics · 2026Article
- Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns.The Prostate · 2026Article
- "Hope at a better chance": perspectives on genetic counseling and testing among black individuals with prostate cancer.Journal of community genetics · 2025Article
- Germline testing for prostate cancer: current state and opportunities for enhanced access.EBioMedicine · 2025Review
- Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.Targeted oncology · 2025Review
- Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.BMC public health · 2024Article
- Germline Mutations and Ancestry in Prostate Cancer.Current oncology reports · 2024Review
- Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race.ClinicoEconomics and outcomes research : CEOR · 2024Article
- Preparing for the unexpected: Recommendations for returning secondary findings in late-stage cancer care.Genetics in medicine : official journal of the American College of Medical Genetics · 2024Article
- Usefulness of podcasts to provide public education on prostate cancer genetics.Prostate cancer and prostatic diseases · 2023Article
- Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.World journal of urology · 2023Article
- Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer:Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Adherence to NCCN Genetic Testing Guidelines in Pancreatic Cancer and Impact on Treatment.The oncologist · 2023Article
- Communicating risk and the landscape of cancer prevention - an exploratory study that examines perceptions of cancer-related genetic counseling and testing among African Americans and Latinos in the Midwest.Journal of community genetics · 2023Article
- Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.JCO precision oncology · 2023Article
- Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans.Journal of clinical medicine · 2022Article
- Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Germline testing is becoming increasingly relevant in prostate cancer (PCa) screening, prognosis, and management. A subset of patients with PCa harbor pathogenic/likely pathogenic variants (P/LPVs) in genes mediating DNA-repair processes, and these P/LPVs have implications for cancer screening, treatment, and cascade testing. As a result, it is recommended that all men with high-risk localized and metastatic PCa undergo routine germline testing. As more PCa patients undergo germline testing, it is important that clinicians and genetics experts recognize current disparities in germline testing rates among racial/ethnic minorities in the United States. The reasons for these disparities are multiple and require similarly manifold consideration to close the germline testing gap and reduce inequities in PCa screening, management, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.